| Bioactivity | Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model[1][2]. |
| In Vivo | Ormutivimab (20 IU/kg；肌肉注射；单剂量) 保护比格犬免受 RABV BD06 的致命攻击[1]。Ormutivimab (20 IU/kg、100 IU/kg；肌注；单剂量) 保护受攻击的 Kunming 小鼠免受各种狂犬病病毒的侵害[1]。 Animal Model: |
| Name | Ormutivimab |
| CAS | 2449086-91-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhai LL, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis. 2022 Mar-Apr;46:102267. [2]. Zhang J, et al. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. Vaccines (Basel). 2022 Jul 29;10(8):1218. |